LY-503430

LY-503430 is an ampakine compound which acts as a positive allosteric modulator of the AMPA receptor. It has been investigated for its potential use in the treatment of schizophrenia, Alzheimer's disease, and attention deficit hyperactivity disorder (ADHD).

Pharmacology

LY-503430 is a potent and selective AMPA receptor potentiator. It enhances AMPA receptor-mediated synaptic responses in vitro and in vivo. The compound has been shown to improve cognitive function in animal models of schizophrenia and Alzheimer's disease.

Clinical Trials

LY-503430 has undergone Phase I clinical trials for the treatment of schizophrenia and Alzheimer's disease. The results of these trials have not been published.

Potential Therapeutic Uses

LY-503430 has potential therapeutic uses in the treatment of cognitive disorders such as schizophrenia, Alzheimer's disease, and ADHD. It may also have potential uses in the treatment of other neurological disorders such as Parkinson's disease and Huntington's disease.

See Also

• AMPA receptor
• Ampakine
• Schizophrenia
• Alzheimer's disease
• Attention deficit hyperactivity disorder

LY-503430 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski